58641-87-5Relevant articles and documents
Compounds advantageous in the treatment of central nervous system diseases and disorders
-
, (2015/12/25)
A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia,
Asymmetric Co(II)-catalyzed cyclopropanation with succinimidyl diazoacetate: General synthesis of chiral cyclopropyl carboxamides
Ruppel, Joshua V.,Gauthier, Ted J.,Snyder, Nicole L.,Perman, Jason A.,Zhang, X. Peter
supporting information; experimental part, p. 2273 - 2276 (2009/10/02)
[Co(P1)] is an effective catalyst for asymmetric cyclopropanation with succinimidyl diazoacetate. The Co(II)-catalyzed reaction is suitable for various olefins, providing the desired cyclopropane succinimidyl esters in high yields and excellent diastereo-
5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS
-
Page/Page column 35; 72-73, (2008/06/13)
This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor. Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less or no agonist activity on the 5-HT2A receptor and/or the 5-HT2B receptor. Compounds of this invention are those of Formula I and pharmaceutically acceptable salts, esters and solvates (including hydrates) wherein variables are defined in the specification hereof.